{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:31:31Z","timestamp":1794281491009,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["I34I19001520001 as CUP"],"award-info":[{"award-number":["I34I19001520001 as CUP"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00204-022-03289-z","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T15:08:21Z","timestamp":1649689701000},"page":"1989-2001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common \u201cdiuretic and masking agent\u201d in doping"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-4532","authenticated-orcid":false,"given":"Francesco P.","family":"Busard\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-5277","authenticated-orcid":false,"given":"Alfredo F.","family":"Lo Faro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-3013","authenticated-orcid":false,"given":"Ascanio","family":"Sirignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-0396","authenticated-orcid":false,"given":"Raffaele","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-9518","authenticated-orcid":false,"given":"Jeremy","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"3289_CR1","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s11255-020-02704-7","volume":"53","author":"S Acar","year":"2021","unstructured":"Acar S, Sanli S, Oztosun C et al (2021) Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. Int Urol Nephrol 53:1839\u20131849","journal-title":"Int Urol Nephrol"},{"key":"3289_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1476-5381.2010.00789.x","volume":"161","author":"AB Cadwallader","year":"2010","unstructured":"Cadwallader AB, de la Torre X, Tieri A, Botr\u00e8 F (2010) The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis. Br J Pharmacol 161:16","journal-title":"Br J Pharmacol"},{"key":"3289_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1373\/clinchem.2016.267575","volume":"63","author":"J Carlier","year":"2017","unstructured":"Carlier J, Diao X, Scheidweiler KB, Huestis MA (2017) Distinguishing intake of new synthetic cannabinoids ADB-PINACA and 5F-ADB-PINACA with human hepatocyte metabolites and high-resolution mass spectrometry. Clin Chem 63:1008\u20131021","journal-title":"Clin Chem"},{"key":"3289_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpba.2018.05.007","volume":"157","author":"J Carlier","year":"2018","unstructured":"Carlier J, Diao X, Huestis MA (2018) Synthetic cannabinoid BB-22 (QUCHIC): human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. J Pharm Biomed Anal 157:27\u201335","journal-title":"J Pharm Biomed Anal"},{"key":"3289_CR5","first-page":"1","volume":"22","author":"J Carlier","year":"2021","unstructured":"Carlier J, Diao X, Giorgetti R et al (2021) Pyrrolidinyl synthetic cathinones \u03b1-PHP and 4F-\u03b1-PVP metabolite profiling using human hepatocyte incubations. Int J Mol Sci 22:1\u201317","journal-title":"Int J Mol Sci"},{"key":"3289_CR6","unstructured":"ChemSpider\u2014search and share chemistry. http:\/\/www.chemspider.com. Accessed 10 Feb 2022"},{"key":"3289_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","volume":"20","author":"RS Cvetkovic","year":"2003","unstructured":"Cvetkovic RS, Perry CM (2003) Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20:919\u2013947","journal-title":"Drugs Aging"},{"key":"3289_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1021\/acs.chemrestox.0c00224","volume":"34","author":"KC De Bruyn","year":"2021","unstructured":"De Bruyn KC, \u0160\u00edcho M, Mazzolari A, Kirchmair J (2021) GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 biotransformations of xenobiotics. Chem Res Toxicol 34:286\u2013299","journal-title":"Chem Res Toxicol"},{"key":"3289_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0731-7085(85)80017-0","volume":"3","author":"FT Delbeke","year":"1985","unstructured":"Delbeke FT, Debackere M (1985) The influence of diuretics on the excretion and metabolism of doping agents\u2014I. Mephentermine. J Pharm Biomed Anal 3:141\u2013148","journal-title":"J Pharm Biomed Anal"},{"key":"3289_CR10","first-page":"134","volume":"36","author":"FT Delbeke","year":"1986","unstructured":"Delbeke FT, Debackere M (1986a) The influence of diuretics on the excretion and metabolism of doping agents II. Phentermine\u2014PubMed. Arzneimittelforschung 36:134\u2013137","journal-title":"Arzneimittelforschung"},{"key":"3289_CR11","first-page":"1413","volume":"36","author":"FT Delbeke","year":"1986","unstructured":"Delbeke FT, Debackere M (1986b) The influence of diuretics on the excretion and metabolism of doping agents III. Etilamfetamine. Arzneimittelforschung 36:1413\u20131416","journal-title":"Arzneimittelforschung"},{"key":"3289_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/bod.2510090203","volume":"9","author":"FT Delbeke","year":"1988","unstructured":"Delbeke FT, Debackere M (1988) The influence of diuretics on the excretion and metabolism of doping agents part iv\u2014caffeine. Biopharm Drug Dispos 9:137\u2013145","journal-title":"Biopharm Drug Dispos"},{"key":"3289_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0731-7085(91)80232-X","volume":"9","author":"FT Delbeke","year":"1991","unstructured":"Delbeke FT, Debackere M (1991a) The influence of diuretics on the excretion and metabolism of doping agents - V. Dimefline J Pharm Biomed Anal 9:23\u201328","journal-title":"Dimefline J Pharm Biomed Anal"},{"key":"3289_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/bdd.2510120105","volume":"12","author":"FT Delbeke","year":"1991","unstructured":"Delbeke FT, Debackere M (1991b) The influence of diuretics on the excretion and metabolism of doping agents: Part VI. Pseudoephedrine. Biopharm Drug Dispos 12:37\u201348","journal-title":"Biopharm Drug Dispos"},{"key":"3289_CR15","doi-asserted-by":"publisher","first-page":"122740","DOI":"10.1016\/j.talanta.2021.122740","volume":"235","author":"A Di Trana","year":"2021","unstructured":"Di Trana A, Brunetti P, Giorgetti R et al (2021) In silico prediction, LC-HRMS\/MS analysis, and targeted\/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites. Talanta 235:122740","journal-title":"Talanta"},{"key":"3289_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11419-016-0326-9","volume":"35","author":"X Diao","year":"2017","unstructured":"Diao X, Carlier J, Zhu M et al (2017a) In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol 35:20\u201332","journal-title":"Forensic Toxicol"},{"key":"3289_CR17","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1373\/clinchem.2017.277152","volume":"63","author":"X Diao","year":"2017","unstructured":"Diao X, Carlier J, Zhu M, Huestis MA (2017b) Human hepatocyte metabolism of novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18. Clin Chem 63:1753\u20131763","journal-title":"Clin Chem"},{"key":"3289_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s11419-018-0404-2","volume":"36","author":"X Diao","year":"2018","unstructured":"Diao X, Carlier J, Zhu M, Huestis MA (2018) Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicol 36:304\u2013312","journal-title":"Forensic Toxicol"},{"key":"3289_CR19","first-page":"141","volume":"29","author":"J Easterbrook","year":"2001","unstructured":"Easterbrook J, Lu C, Sakai Y, Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141\u2013144","journal-title":"Drug Metab Dispos"},{"key":"3289_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.trac.2008.10.001","volume":"27","author":"MJ Garc\u00eda-Gal\u00e1n","year":"2008","unstructured":"Garc\u00eda-Gal\u00e1n MJ, D\u00edaz-Cruz S, Barcelo D (2008) Identification and determination of metabolites and degradation products of sulfonamide antibiotics: advanced MS analysis of metabolites and degradation products\u2014II. TrAC Trends Anal Chem 27:1008\u20131022","journal-title":"TrAC Trends Anal Chem"},{"key":"3289_CR21","volume-title":"Pharmacological basis of therapeutics","author":"LS Goodman","year":"1975","unstructured":"Goodman LS, Gilman A (1975) Pharmacological basis of therapeutics, 5th edn. Macmillan, New York City","edition":"5"},{"key":"3289_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/JCP.0000000000000529","volume":"36","author":"AJ Hampson","year":"2016","unstructured":"Hampson AJ, Babalonis S, Lofwall MR et al (2016) A pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials. J Clin Psychopharmacol 36:324\u2013332","journal-title":"J Clin Psychopharmacol"},{"key":"3289_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/cpt.1929","volume":"108","author":"AJ Hampson","year":"2020","unstructured":"Hampson AJ, Schroeder JR, Ellefsen KN et al (2020) Subtherapeutic acetazolamide doses as a noninvasive method for assessing medication adherence. Clin Pharmacol Ther 108:1203\u20131212","journal-title":"Clin Pharmacol Ther"},{"key":"3289_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.aca.2008.04.043","volume":"627","author":"BO Keller","year":"2008","unstructured":"Keller BO, Sui J, Young AB, Whittal RM (2008) Interferences and contaminants encountered in modern mass spectrometry. Anal Chim Acta 627:71\u201381","journal-title":"Anal Chim Acta"},{"key":"3289_CR25","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/dta.3100","volume":"13","author":"P Kintz","year":"2021","unstructured":"Kintz P, Gheddar L, Ameline A, Raul J (2021) Hair testing for acetazolamide as an evidence of the use of a contaminated dietary supplement. Drug Test Anal 13:1584\u20131588","journal-title":"Drug Test Anal"},{"key":"3289_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/187231211794455299","volume":"5","author":"K Kishida","year":"2011","unstructured":"Kishida K, Yamamura N, Iwai Y et al (2011) The metabolism of methazolamide\u2014identification of metabolites in guinea pig urine. Drug Metab Lett 5:45\u201354","journal-title":"Drug Metab Lett"},{"key":"3289_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/dta.2342","volume":"10","author":"A Kotronoulas","year":"2018","unstructured":"Kotronoulas A, Gomez-G\u00f3mez \u00c0, Fabregat A et al (2018) Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part II: intramuscular administration. Drug Test Anal 10:849\u2013859","journal-title":"Drug Test Anal"},{"key":"3289_CR28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/dta.3055","volume":"13","author":"AF Lo Faro","year":"2021","unstructured":"Lo Faro AF, Tini A, Gottardi M et al (2021) Development and validation of a fast ultra high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS\/MS) method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair. Drug Test Anal 13:1552\u20131560","journal-title":"Drug Test Anal"},{"key":"3289_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","volume":"47","author":"TH Maren","year":"1967","unstructured":"Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 47:595\u2013781","journal-title":"Physiol Rev"},{"key":"3289_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1139\/y74-138","volume":"52","author":"TH Maren","year":"1974","unstructured":"Maren TH (1974) Chemistry of the renal reabsorption of bicarbonate. Can J Physiol Pharmacol 52:1041\u20131050","journal-title":"Can J Physiol Pharmacol"},{"key":"3289_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2165\/00003088-200241030-00004","volume":"41","author":"J Martens-Lobenhoffer","year":"2002","unstructured":"Martens-Lobenhoffer J, Banditt P (2002) Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet 41:197\u2013205","journal-title":"Clin Pharmacokinet"},{"key":"3289_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00216-012-5807-z","volume":"403","author":"MR Meyer","year":"2012","unstructured":"Meyer MR, Maurer HH (2012) Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem 403:1221\u20131231","journal-title":"Anal Bioanal Chem"},{"key":"3289_CR33","unstructured":"mzCloud\u2014Advanced mass spectral database. https:\/\/www.mzcloud.org. Accessed 10 Feb 2022"},{"issue":"Suppl 1","key":"3289_CR34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0773.1984.tb03625.x","volume":"54","author":"B Odlind","year":"1984","unstructured":"Odlind B (1984) Site and mechanism of the action of diuretics. Acta Pharmacol Toxicol (copenh) 54(Suppl 1):5\u201315","journal-title":"Acta Pharmacol Toxicol (copenh)"},{"key":"3289_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fchem.2020.00435","volume":"8","author":"M Putz","year":"2020","unstructured":"Putz M, Piper T, Thevis M (2020) Identification of trenbolone metabolites using hydrogen isotope ratio mass spectrometry and liquid chromatography\/high accuracy\/high resolution mass spectrometry for doping control analysis. Front Chem 8:435","journal-title":"Front Chem"},{"key":"3289_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/1872312811666170127160931","volume":"10","author":"T Sasabe","year":"2017","unstructured":"Sasabe T, Maeda S, Kishida K et al (2017) The metabolism of methazolamide in immortalized human keratinocytes, HaCaT cells. Drug Metab Lett 10:295\u2013305","journal-title":"Drug Metab Lett"},{"key":"3289_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-94-007-7359-2_17","volume":"75","author":"A Scozzafava","year":"2014","unstructured":"Scozzafava A, Supuran CT (2014) Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem 75:349\u2013359","journal-title":"Subcell Biochem"},{"key":"3289_CR38","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/mus.26009","volume":"57","author":"JM Statland","year":"2018","unstructured":"Statland JM, Fontaine B, Hanna MG et al (2018) Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve 57:522\u2013530","journal-title":"Muscle Nerve"},{"key":"3289_CR39","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/bioinformatics\/btz695","volume":"36","author":"C Stork","year":"2020","unstructured":"Stork C, Embruch G, \u0160\u00edcho M et al (2020) NERDD: a web portal providing access to in silico tools for drug discovery. Bioinformatics 36:1291\u20131292","journal-title":"Bioinformatics"},{"key":"3289_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/14737175.2015.1066675","volume":"15","author":"CT Supuran","year":"2015","unstructured":"Supuran CT (2015) Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 15:851\u2013856","journal-title":"Expert Rev Neurother"},{"key":"3289_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1517\/13543776.10.5.575","volume":"10","author":"CT Supuran","year":"2000","unstructured":"Supuran CT, Scozzafava A (2000) Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 10:575\u2013600","journal-title":"Expert Opin Ther Pat"},{"key":"3289_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/med.10025","volume":"23","author":"CT Supuran","year":"2003","unstructured":"Supuran CT, Scozzafava A, Casini A (2003) Carbonic anhydrase inhibitors. Med Res Rev 23:146\u2013189","journal-title":"Med Res Rev"},{"key":"3289_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4155\/bio.15.237","volume":"8","author":"MJ Swortwood","year":"2016","unstructured":"Swortwood MJ, Carlier J, Ellefsen KN et al (2016) In vitro, in vivo and in silico metabolic profiling of \u03b1-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis 8:65\u201382","journal-title":"Bioanalysis"},{"key":"3289_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1124\/dmd.121.000635","volume":"49","author":"I Teslenko","year":"2021","unstructured":"Teslenko I, Watson CJW, Xia Z et al (2021) Characterization of cytosolic glutathione S-transferases involved in the metabolism of the aromatase inhibitor, exemestane. Drug Metab Dispos 49:1047\u20131055","journal-title":"Drug Metab Dispos"},{"key":"3289_CR45","doi-asserted-by":"publisher","first-page":"k2153","DOI":"10.1136\/bmj.k2153","volume":"361","author":"J Williamson","year":"2018","unstructured":"Williamson J, Oakeshott P, Dallimore J (2018) Altitude sickness and acetazolamide. BMJ 361:k2153","journal-title":"BMJ"},{"key":"3289_CR46","unstructured":"World Anti-Doping Agency (WADA) (2011) 2010 Adverse analytical findings and atypical findings reported by accredited laboratories. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/WADA_2010_Laboratory_Statistics_Report.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR47","unstructured":"World Anti-Doping Agency (WADA) (2012) 2011 laboratory testing figures reported by accredited laboratories. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/WADA-2011-Laboratory-Testing-Figures.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR48","unstructured":"World Anti-Doping Agency (WADA) (2013) 2012 anti-doping testing figures report. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/WADA-2012-Anti-Doping-Testing-Figures-Report-EN.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR49","unstructured":"World Anti-Doping Agency (WADA) (2014) 2013 anti-doping testing figures report. https:\/\/www.wada-ama.org\/sites\/default\/files\/wada_2013_anti-doping_testing_figures_report_en.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR50","unstructured":"World Anti-Doping Agency (WADA) (2015) 2014 anti-doping testing figures report. https:\/\/www.wada-ama.org\/sites\/default\/files\/wada_2014_anti-doping-testing-figures_full-report_en.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR51","unstructured":"World Anti-Doping Agency (WADA) (2016) 2015 anti-doping testing figures. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2015_wada_anti-doping_testing_figures_report_0.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR52","unstructured":"World Anti-Doping Agency (WADA) (2017) 2016 anti-doping testing figures. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2016_anti-doping_testing_figures.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR53","unstructured":"World Anti-Doping Agency (WADA) (2018) 2017 anti-doping testing figures. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2017_anti-doping_testing_figures_en_0.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR54","unstructured":"World Anti-Doping Agency (WADA) (2019) 2018 anti-doping testing figures. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2018_testing_figures_report.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR55","unstructured":"World Anti-Doping Agency (WADA) (2020) 2019 anti-doping testing figures. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2019_anti-doping_testing_figures_en.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR56","unstructured":"World Anti-Doping Agency (WADA) (2021a) World anti-doping code - International standard prohibited list. https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2021list_en.pdf. Accessed 10 Feb 2022"},{"key":"3289_CR57","unstructured":"World Anti-Doping Agency (WADA) (2021b) WADA publishes stakeholder notices regarding potential contamination cases related to meat and diuretics. https:\/\/www.wada-ama.org\/en\/media\/news\/2021b-06\/wada-publishes-stakeholder-notices-regarding-potential-contamination-cases. Accessed 10 Feb 2022"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-022-03289-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:56:28Z","timestamp":1700412988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-022-03289-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1007\/s00204-022-03289-z","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of CERM (263\/2020, October 1, 2020). Informed consent was obtained from all patients involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}